Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) Short Interest Update

Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) saw a significant decrease in short interest during the month of December. As of December 15th, there was short interest totaling 407,422 shares, a decrease of 31.2% from the November 30th total of 592,267 shares. Based on an average trading volume of 240,762 shares, the short-interest ratio is presently 1.7 days. Currently, 1.6% of the company’s stock are sold short. Currently, 1.6% of the company’s stock are sold short. Based on an average trading volume of 240,762 shares, the short-interest ratio is presently 1.7 days.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Adial Pharmaceuticals stock. Citadel Advisors LLC purchased a new stake in Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 143,791 shares of the company’s stock, valued at approximately $51,000. Citadel Advisors LLC owned approximately 0.60% of Adial Pharmaceuticals as of its most recent SEC filing. Institutional investors own 16.41% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on the stock. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Adial Pharmaceuticals in a report on Wednesday, October 8th. Maxim Group raised Adial Pharmaceuticals from a “hold” rating to a “buy” rating and set a $1.50 price objective for the company in a research report on Tuesday, September 30th. One equities research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Adial Pharmaceuticals has an average rating of “Hold” and an average target price of $1.50.

Adial Pharmaceuticals Trading Down 1.2%

NASDAQ ADIL opened at $0.23 on Wednesday. Adial Pharmaceuticals has a 12-month low of $0.22 and a 12-month high of $1.30. The company has a fifty day simple moving average of $0.31 and a two-hundred day simple moving average of $0.35. The stock has a market cap of $6.09 million, a P/E ratio of -0.30 and a beta of 1.11.

Adial Pharmaceuticals (NASDAQ:ADIL) last announced its quarterly earnings data on Thursday, November 13th. The company reported ($0.08) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.01. As a group, sell-side analysts forecast that Adial Pharmaceuticals will post -1.53 earnings per share for the current year.

Adial Pharmaceuticals Company Profile

Adial Pharmaceuticals, Inc, incorporated in Delaware and founded in 2003, is a clinical-stage specialty pharmaceutical company dedicated to the development of treatments for addiction disorders and central nervous system conditions. The company’s mission centers on creating novel modalities designed to enhance patient adherence and clinical outcomes, particularly in areas of high unmet medical need. Adial leverages sustained-release delivery technologies to address the challenges associated with oral medication regimens in addiction therapy.

The company’s lead product candidate, AD04, is a bioerodible subcutaneous implant engineered to deliver naltrexone continuously over a multi-month period for individuals with alcohol dependence.